Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00087698 · ClinicalTrials.gov registry record · Phase 2

Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma

A Phase 2 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
77
Enrollment target

NCT00087698: Completed Phase 2 study, sponsored by Eli Lilly and Company.

NCT00087698 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 77 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00087698, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
77 participants
Enrollment target

Study Summary

This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the cancer returns and if so, where, will also be monitored.

Primary Outcome

Number of participants with results of pathological review that indicated a complete response. Pathological complete response should be evaluated at the time of surgery (Extrapleural Pneumonectomy \[EPP\]). Resected tissue or pleural fluid should be sent for pathological and histological evaluation.

Interventions

  • DRUG cisplatin
  • DRUG pemetrexed

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2003-09
Est. Completion 2008-02
Phase Phase 2
Eli Lilly and Company

1,341 total trials

What the finished NCT00087698 record still lists

NCT00087698 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower).

The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.

NCT00087698 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00087698 about?

NCT00087698 is a clinical study titled "Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma". This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the ca...

What is the current status of trial NCT00087698?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2003-09. Estimated completion is 2008-02.

What interventions are being tested in trial NCT00087698?

The interventions under investigation include: cisplatin (DRUG), pemetrexed (DRUG).

Who is sponsoring clinical trial NCT00087698?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00087698's enrollment target sits among peer trials

77 891st of 2000 higher than 1,108 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02127398 · 77 participants · Phase 2

    Stool Transplants to Treat Refractory Clostridium Difficile Colitis

  • NCT04159103 · 77 participants · Phase 1

    Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

  • NCT04683003 · 77 participants · Phase 3

    A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

  • NCT05004116 · 77 participants · Phase 1

    A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00087698, the US trial registry maintained by the National Library of Medicine. NCT00087698 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.